rosoxacin

Rosoxacin is a first-generation quinolone antibiotic used primarily for the treatment of urinary tract infections and certain sexually transmitted diseases, including uncomplicated acute gonococcal urethritis. It is effective against both Gram-positive and Gram-negative bacteria, including penicillin-resistant strains. The drug acts by binding to and inhibiting bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination in bacteria. Rosoxacin was developed in 1978 by George Lesher and colleagues at Winthrop-Stearns (now part of Sanofi), as an extension of research on nalidixic acid. It is administered orally as a single dose regimen[1][2][4][6][7].

Brand names

Eradacil

Other names

Winuron40034-42-2